UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

doi:10.1002/bcp.70659

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology - 1 Sept 2026

Chauhan Dharmisha, Dello Russo Cinzia, Thompson Jack, Hughes Dyfrig A, Payne Katherine, Tsakiroglou Maria, Ross Paul, Chauhan Rena, Jenkinson Simon, Keen Jessica, Harding Sophie, Lau Eleanor, Braun Michael, Agarwal Roshan, Adams Richard, Rolf Elisabeth, Al-Sheikhli Farah, Mitchell Sarah, Hammond Ruth, Roberts Rosie, Cairns Lorna, Heggarty Shirley, Graham Janet, Mencel Justin, Pirmohamed Munir

Abstract excerpt

Irinotecan, a topoisomerase I inhibitor, is available as both non-pegylated and pegylated formulations. The non-pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy. However, it is also used off-label across a range of gastrointestinal malignancies and in rare malignancies such as glioblastoma and sarcomas. The pegylated formulation is...

Topics

Join the communities discussing this publication.

Camptothecin
Genotype
Glucuronosyltransferase
Irinotecan

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Pharmacogenetics

Pharmacogenomic Testing

Topoisomerase I Inhibitors

United Kingdom

Source

Open in PubMed Open full text

Identifiers

PMID: 42389808
DOI: 10.1002/bcp.70659
PMCID: PMC13519796

Genes

UGT1A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.